PAX1/JAM3 Methylation and HPV E6/E7 mRNA Testing for the Detection of Cervical High-Grade Lesions(CIN2+):Diagnostic Performance and Combined Application
Cao Jianing1, Liu Jing2, Han Lili2,*
1. The First Affiliated Hospital of Shihezi University,Shihezi 832000,Xinjiang,CHINA; 2. Department of Gynecology,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,Xinjiang,CHINA
Abstract：Objective To evaluate the diagnostic value of human papilloma virus(HPV)E6/E7 mRNA testing and PAX1/JAM3 gene promoter methylation analysis for high-grade cervical intraepithelial neoplasia(CIN2+),and to assess strategies for their combined use.Methods A total of 196 women with abnormal cervical screening results were enrolled.All participants underwent testing for HPV E6/E7 mRNA and PAX1/JAM3 promoter methylation.Using cervical biopsy histopathology as the gold standard,the positive rates of both markers were analyzed across different cervical lesion grades(including viralinfection,CIN I,CIN II,CIN III,and cervical cancer).The diagnostic performance of each marker alone and in combination was evaluated.Results The positive rates of both HPV E6/E7 mRNA and PAX1/JAM3 methylation increased significantly with the severity of cervical lesions(P<0.01).Multivariate logistic regression analysis identified both as independent risk factors for high-grade cervical lesions(CIN2+),with odds ratios(ORs)of 5.90 and 5.77,respectively.PAX1/JAM3 methylation had a greater specificity for diagnosing CIN2+(82.30%)and AUC(0.671).In the combination test,a serial(sequential)test approach greatly improved the specificity,up to 92.92%(AUC=0.687),while an approach in parallel significantly increased sensitivity up to 87.95%(AUC=0.674).Conclusion The HPV E6/E7 mRNA test has a high sensitivity and can be used as the primary method of cervical cancer screening;the PAX1/JAM3 methylation test has a high specificity,suggests considerable utility in triaging primary screen positive women.Combined usage of these two markers has complementary benefits,improving detection and accurate characterization of cervix pathology.
曹嘉宁, 刘靖, 韩莉莉. PAX1/JAM3甲基化与HPV E6/E7 mRNA检测对宫颈高级别病变的诊断效能及联合策略研究[J]. 哈尔滨医药, 2026, 46(3): 26-31.
Cao Jianing, Liu Jing, Han Lili. PAX1/JAM3 Methylation and HPV E6/E7 mRNA Testing for the Detection of Cervical High-Grade Lesions(CIN2+):Diagnostic Performance and Combined Application. journal1, 2026, 46(3): 26-31.
[1] CURRY S J,KRIST A H,OWENS D K,et al.Screening for cervical cancer:US Preventive Services Task Force recommendation statement[J].JAMA,2018,320(7):674-686. [2] KOLIOPOULOS G,NYAGA V N,SANTESSON M,et al.Cytology versus HPV testing for cervical cancer screening in the general population[J].Cochrane Database of Systematic Reviews,2017(8):CD008587. [3] GUPTA S M,WARKE H,CHAUDHARI H,et al.Human Papillomavirus E6/E7 oncogene transcripts as biomarkers for the early detection of cervical cancer[J].Journal of Medical Virology,2022,94(7):3368-3375. [4] IKENBERG H,BONDE J,OLESEN T B,et al.Screening for cervical cancer precursors with the Aptima HPV E6/E7 mRNA assay in a primary setting:A Danish nationwide study[J].International Journal of Cancer,2020 147(3):711-720. [5] CUZICK J,CADMAN L,MESHER D,et al.Performance of the Aptima HPV E6/E7 mRNA assay in a large cohort of women attending primary cervical screening in England[J].Journal of Clinical Virology,2021,141:104904. [6] 李雅,刘慧,任静静,等.FAM19A4、PAX1及miRNA124-2基因启动子区甲基化在宫颈病变早期诊断中的价值[J].中国癌症杂志,2024,34(8):734-744. [7] LI B,GUO R X,LAI T J,et al.The application of PAX1 methylation detection and HPV E6/E7 mRNA detection in cervical cancer screening[J].The Journal of Obstetrics and Gynaecology Research,2021,47(8):2720-2728. [8] KELLY H,BENAVIDENTE Y,PAVON M A,et al.Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia(CIN2+):a systematic review and meta-analysis[J].British Journal of Cancer,2019,121:954-965. [9] VERHOEF L,VAN ZON H,SIEBERS A G,et al.JAM3 methylation as a triage marker for hrHPV-positive women:A large multicenter study in the Netherlands[J].International Journal of Cancer,2022,151(5):756-765. [10] KURMAN R J,CARCANGIU M L,HERRINGTON C S,et al.WHO classification of tumours of female reproductive organs[M].4th ed.Lyon:IARC Press,2014:184-189. [11] ZHAO Y,DENG T,ZHAI Y,et al.Performance of HPV E6/E7 mRNA versus DNA testing in primary cervical cancer screening:a large-scale population-based study in China[J].Infectious Agents and Cancer,2023,18(1):10. [12] MAVER P J,POLJAK M,SEME K,et al.The role of HPV E6/E7 mRNA testing in the management of women after treatment for CIN2+ lesions:A systematic review and meta-analysis[J].Cancer Epidemiology,2021,72:101930. [13] BONDE J,FLOORE A,EJEGOD D,et al.Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women:A large European multicenter study[J].International Journal of Cancer,2020,146(5):1234-1244. [14] VINK F J,DICK S,HEIDEMAN D A M,et al.The clinical value of host DNA methylation markers in triaging HPV-positive women:a large cohort study[J].British Journal of Cancer,2021,124(6):1113-1119. [15] LORINCZ A T,SCIBIOR-BENTKOWSKA D,REUTER C.Multicentre evaluation of a dual methylation test for the detection of cervical precancer in self-collected and clinician-collected samples[J].International Journal of Cancer,2023,152(5):901-911. [16] ANISIMOVA M,JAIN M,SHCHERBAKOVA L,et al.Detection of CADM1,MAL,and PAX1 methylation by ddPCR for triage of HPV-positive cervical lesions[J].Biomedicines,2025,13(6):1450. [17] LIAO Y,ZHANG H,ZHAO Y,et al.Diagnostic value of PAX1 methylated DNA in cervical cancer:A meta-analysis[J].Medicine,2021,100(11):e24966. [18] TORNéS M L,MONGUI E,ORTIZ R,et al.Dynamics of HPV16 DNA methylation and viral load in incident infections:A longitudinal study[J].The Journal of Infectious Diseases,2022,225(8):1425-1433.
2026, Vol. 46 
